(AOF) – The editorial staff has clarified the article published this Wednesday about Inventiva. Inventiva shows 11 million euros of cash and cash equivalents as of March 31. Short-term deposits reach 0.1 million euros and long-term deposits 19.1 million euros, giving a total of 31 million euros. The long-term deposit with a duration of two years is, however, accessible before expiry of the term with 31 days’ notice and is considered liquid by the company.
The biotech specializing in the clinical development of small molecules administered orally for the treatment of non-alcoholic steatohepatitis (“NASH”) estimates that these funds should allow it to finance its activities until the start of the third quarter of 2024. Inventiva specifies that it did not generate revenue in the first quarter of 2024, as it did for the first quarter of 2023.
The first visit of the last patient of the Phase III NATIV3 clinical study evaluating the product lanifibranor in MASH/NASH is planned for the first half of 2024.
© 2024 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
